why choose us

First received: August 24, 2023

Clinical Trial: A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia

Study Status: Completed

Recruit Status: RECRUITING

Condition: Refractory Acute Myeloid Leukemia

Study Type: INTERVENTIONAL


Official Title: Phase I Trial of CLEc12a (CD371) Targeted ArmoRed Immune Effector Cells in Patients With Relapsed/Refractory Acute Myeloid Leukemia (CLEAR-AML)

Brief Summary: The purpose of this study is to find out whether CD371-YSNVZ-IL18 CAR T cells are safe, and to look for the highest dose of CD371-YSNVZ-IL18 CAR T cells that cause few or mild side effects in participants.

Read more